New England Biolabs® launches the NEBNext® Flu A Integrated Indexing Primer Module to advance Influenza A surveillance and sequencing

Streamlined, high-throughput sequencing of Influenza A virus with integrated indexing for Oxford Nanopore Technologies® platforms

IPSWICH, Mass., Nov. 13, 2025 /PRNewswire/ -- New England Biolabs (NEB^®) today announces the release of the NEBNext Flu A Integrated Indexing Primer Module (NEB #E3436), designed to streamline and scale the sequencing of Influenza A virus from a range of species and sample types using Oxford Nanopore Technologies (ONT) platforms. This launch marks a significant step forward in enabling rapid, high-throughput surveillance of seasonal and emerging flu subtypes (e.g., H3N2, H1N1, and H5N1).

Developed in collaboration with the Johns Hopkins Applied Physics Laboratory (APL), a university affiliated research center advancing science and technology for global health resilience and security, the primer module supports a multi-segment RT-PCR workflow with integrated indexing ("iiMS-PCR"), allowing up to 48 samples to be sequenced in a run. The module is optimized for use in surveillance of zoonotic pathogens, public health labs, academic research and wastewater-based epidemiology programs.

"To effectively limit the spread of emerging biological threats—such as highly pathogenic avian influenza—genetic characterization methods must become as fast and simple to perform as diagnostic assays. Streamlined approaches to enable low-cost, high-throughput whole-genome sequencing support rapid local response efforts, ensuring that genomic data can be quickly integrated into regional and global monitoring systems to strengthen predictive modeling and preparedness capabilities," said Peter Thielen, a molecular biologist at APL.

According to Dr. Erik Karlsson, Head of the Virology Unit at Institut Pasteur du Cambodge, "The iiMS workflow has been pivotal for rapid response to H5 outbreaks in both poultry and humans. It enables us to confirm poultry-to-human transmission within 24 hours, which is essential for timely public-health action and risk communication. We also rely on this platform weekly for routine assessment of circulating influenza strains across Cambodia." He adds, "The simplification of the workflow translates directly to rapid establishment in low-resource settings, allowing surveillance to happen where it is needed most and ensuring advanced genomic tools are available at the true frontlines of emerging zoonotic threats."

The NEBNext Flu A Integrated Indexing Primer Module includes reagents for indexed cDNA synthesis, amplification, and library preparation, and it works seamlessly with NEB's Monarch^® Mag Viral DNA/RNA Extraction Kit, LunaScript^® Multiplex One-Step RT-PCR Kit, and ONT's Native Barcoding Workflow. The protocol was proactively released on protocols.io to enable early access to this helpful workflow and has since been validated in diverse sample types, including clinical samples, agricultural products, and wastewater.

"Influenza A remains a persistent global health challenge due to its rapid evolution and seasonal variability," said Betsy Young, Ph.D., Senior Product Marketing Manager for Next Generation Sequencing at NEB. "With this primer module, we're equipping researchers and surveillance teams with a robust, scalable workflow to track genetic changes and inform deployment of public health resources."

The release of this product expands NEB's portfolio of reagents that support infectious disease research, and complements NEB's existing offerings for SARS-CoV-2, RSV, and other respiratory pathogens.

For more information, please visit www.neb.com/E3436, or contact NEB Technical Support at [email protected].

About New England Biolabs

For over 50 years, New England Biolabs (NEB) has pioneered the discovery and production of innovative products tailored for molecular biology research. Our commitment to scientific discovery is evident in all that we do, including our ever-expanding product portfolio, investment in our basic and applied research program, and support of customers' research in academia and industry, including cutting-edge technologies for use in molecular diagnostics and nucleic-acid vaccines development. Guided by our founding principles, NEB proactively invests in efforts to improve the well-being of our employees, surrounding communities, as well as the future of our planet. NEB remains a privately held company with global reach, supported by our headquarters in Ipswich, MA, USA, subsidiary offices in 10 countries, and over 60 distribution partners around the world. For more information about New England Biolabs, visit www.neb.com.

NEW ENGLAND BIOLABS^®, NEB^®, NEBNEXT^®, MONARCH^® and LUNASCRIPT^® are registered trademarks of New England Biolabs, Inc.

SOURCE New England Biolabs, Inc.